Targeting p53 for Cancer Immunotherapy
Author Information
Author(s): Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H
Primary Institution: Wakayama Medical School; The University of Tokyo
Hypothesis
Can p53-derived peptides elicit anti-tumour cytotoxic T lymphocytes in vitro?
Conclusion
The study identified a p53 peptide that can effectively induce cytotoxic T lymphocytes to target tumour cells in HLA-A24-positive patients.
Supporting Evidence
- Mutations in the p53 gene are common in human tumours.
- Wild-type p53 is a promising target for cancer immunotherapy.
- The identified peptide, p53-161, can induce CTL lines that target specific tumour cells.
Takeaway
Scientists found a way to use a part of a protein called p53 to help the body's immune system fight cancer cells.
Methodology
The study tested p53 peptides for their ability to induce cytotoxic T lymphocytes using CD8+ T lymphocytes from healthy donors and dendritic cells as antigen-presenting cells.
Participant Demographics
Healthy donors provided peripheral blood mononuclear cells.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website